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Genetic and serum markers in human host can predict leprosy susceptibility per se as well as be useful in classiﬁcation and/or
predictionofclinicalvariantsandimmunologicalresponsesinleprosy.Adequateandtimelyassessmentofpotentialrisksassociated
withthese38hostleprosygenescoulddiminishepidemiologicalburdenandimprovelifequalityofpatientswiththisstillprevalent
mycobacterial disease.
1.Introduction
In recent years, evidence has accumulated for so-called hu-
man “multidisease susceptibility genes” that play a role in
several infectious and noninfectious diseases [1], and genes
presumably more speciﬁc on its clinical impact when dys-
functional, that probably do not predispose to the disease
per se but to a clinical phenotype when the disease is already
present [2]. A decline in leprosy research, probably for the
erroneous belief that the battle is won, has left unanswered
questionsregardingtheexactmechanismofdiseaseinfection
and progression. Addressing these questions could help in
the ﬁnal eradication of leprosy [3].
Human leprosy (or Hansen disease) is a chronic granulo-
matous infectious disease caused by the obligate intracellular
organism Mycobacterium leprae [4, 5]. Leprosy is still an
important health problem worldwide, with the highest
incidences in Asia, Africa, and Latin America [6]. In 2008,
∼250,000 new cases of leprosy were reported to World
Health Organization [7]. The high concordance rates for
leprosy infection when monozygotic and dizygotic twins
are compared (84.55% versus 18.35%, resp., media of two
independent reports) [7]a sw e l la sl o c it h a ta r el i n k e do r
associated with leprosy, reveal a strong genetic component
in the susceptibility and response to the infection with M.
leprae. Furthermore, complex segregation analyses suggest
an oligogenic model of leprosy susceptibility, with a few
major genes inﬂuencing disease and several additional genes
and variations causing subtle eﬀects on disease outcome
[8]. The origin of transmission of M. leprae is mainly from
untreated lepromatous patients [9] and the people most
probableinfected(leprosyperse)arepatient’scontactswhose
carry susceptibility alleles in loci 20p12 [10], TNFA [11],
as well as PARK2 and PACRG genes [12]. Genetic variants
in human host, mainly single nucleotide polymorphisms
(SNPs) can predict susceptibility to leprosy per se and
to clinical variants when leprosy is already present [2, 8,
13]. Even when death due to leprosy, caused by laryngeal
obstruction, is uncommon [14], adequate and opportune
detection of potential risks could diminish epidemiological
burden and improve life quality of patients with this still
unerradicated mycobacterial disease.
2. LeprosyClassiﬁcation
2.1. Ridley-Jopling Classiﬁcation. Once the infection in the
patient is conﬁrmed, it is important to classify leprosy in
order to determine the appropriate treatment and predict
risk of complications [9] as physical deformities, sensorial
loss, and permanent nerve damage [14]. Since 1940, the
drug to treat leprosy was dapsone, but today a multi-
drug scheme is recommended [14]. Ridley-Jopling clas-
siﬁcation uses histopathological and clinical features and
the bacteriological index as well. It classiﬁes leprosy in2 Journal of Tropical Medicine
tuberculoid (TT), borderline tuberculoid (BT), borderline
(BB), borderline-lepromatous (BL), and lepromatous (LL)
categories. The diﬀerent categories usually correlate with
host immune response. Indeterminate leprosy is an earlier
nondeﬁned state [9, 15]. TT patients present a limited num-
ber of hypopigmented, anesthetic skin lesions with micro-
scopically undistinguishable bacteria. The correlated TH1-
cell-mediated immune (CMI) response (IL-2, IL-6, IL-12,
IFN-γ, and TNF) promotes the formation of delineated
granulomas—central areas of infected macrophages, often
fused into multinucleate giant cells, surrounded by T cells—
which suggested function in infection control is still con-
troversial [16, 17] and data on M. marinum suggesting a
role in infection dissemination seems interesting to test in
human leprosy [18]. Conversely, LL cases present numerous
sensitive or anesthetic skin lesions with high bacillary loads.
LL if untreated may slowly progress to bacteremia [14].
The correlated TH2-antibody response (IL-4, IL-5, IL-10)
impedes granuloma formation, allowing for uncontrolled
bacterial replication and continuous inﬁltration of the skin
and nerves. Borderline forms, that is, borderline-tuberculoid
(BT), borderline (BB), and borderline-lepromatous (BL),
comprise the majority of cases. These individuals present
intermediate clinical and histological phenotypes resulting
from immunologically unstable responses [7]. The incuba-
tion period between infection and clinical disease can vary
from some months to up to 30 years, with a mean period of
4y e a r sf o rT Ta n d1 0y e a r sf o rL L[ 19].
2.2. WHO Operational Classiﬁcation: Multibacillary and Pau-
cibacillary. Another leprosy classiﬁcation proposed by the
World Health Organization (WHO) recognizes the pau-
cibacillary (PB) and multibacillary (MB) forms, in which the
patient presents with 1–5 skin lesions and 6 or more, respec-
tively[20].PatientswithPBdiseasepresentverylowbacterial
counts, exhibiting localized infection and lesions character-
ized by expression of type 1 (TH1) T helper lymphocyte-
related cytokines (cell-mediated immunity) as IL-2, IL-6, IL-
12, IFN-γ, and TNF. Patients presenting MB form are more
susceptible to the pathogen and exhibit systemic infection
and lesions expressing TH2 cytokines (humoral immunity)
[2, 7, 21]. Multibacillary leprosy roughly includes BB, BL,
and LL forms, and paucibacillary the TT and BT forms [7,
21]. For a complete table of polymorphisms associated with
leprosy types according to WHO classiﬁcation, see Table 1.
3. Immunological Reactions and Nerve
Damage inLeprosy
3.1. Mitsuda Response. The standard measure of cell medi-
ated immunity (CMI) against M. leprae is the Mitsuda re-
sponse [4], a delayed granulomatous skin reaction elicited by
theintradermalinjectionofheat-killedMycobacterium leprae
formulations—lepromin is one example—and measured 21
to 28 days after inoculation [21]. Although the Mitsuda test
has been developed to assess immune response to live M.
leprae in natural conditions of infection, other microbial
agentsinﬂuencethistest,suchaslivebacilleCalmette-Guerin
(BCG) vaccine, and M. tuberculosis. Therefore, the Mitsuda
test reﬂects the ability to develop an immune granuloma
after mycobacterial infection but is not a marker for speciﬁc
immune responses to the leprosy bacillus and is not related
to clinical variant in leprosy patients [13].
3.2. Type I Reactions: Reversal Reaction. Reversal reactions
(RRs, oka type I reactions) represent the acute immune
episodes of TH1 inﬂammatory response to M. leprae antigens
that occur in skin and/or nerves and are the leading cause
of neurological impairment in leprosy patients. The skin
lesions become acutely inﬂamed and oedematous and may
ulcerate. Oedema of the hands, feet, and face can also be a
feature of a reaction, but systemic symptoms are unusual.
They occur most frequently in borderline categories (BL, BT,
BB) with a frequency of 30% in these patients [9]o ri nM B
patients, and age is a relevant additional risk factor for both
RR occurrence and sequelae after RR treatment [32]. RR are
frequently recurrent and this can lead to nerve damage. RR
can occur at any time but are frequently seen after starting
multidrug therapy (MDT) or during the puerperium [9].
3.3. Type II Reactions: Erythema Nodosum Leprosum. Ery-
thema nodosum leprosum (ENL) has a prevalence in leprosy
patients of 24%. ENL is a systemic immune reaction which
can occur in LL (up to 50% of LL cases) and borderline
patients (9% of BL patients) and is postulated to be
caused by extravascular deposition of immune complexes
(ICs) resulting in neutrophil inﬁltration and complement
activation. (See C3 and C4B g e n e sb e l o w . )T h e r ea r et h r e e
subclinical types of ENL, named single acute ENL (8% of
cases), multiple acute ENL (repeated discrete episodes), and
chronic ENL (continuous, longer, and more severe episodes,
62.5% of cases) [33]. ENL aﬀects many organs with an acute
onset but it can evolve into a chronic phase and it can be
recurrent. ENL produces fever and in the skin painful tender
red papules or nodules which occur in crops often aﬀecting
the face and extensor surfaces of the limbs. The lesions may
be superﬁcial or deep causing a panniculitis. Bullous ENL
has been described and lesions may ulcerate. Subcutaneous
tissue involvement may lead to tethering and ﬁxation to
joints causing loss of function. ENL reactions may also
produce uveitis, neuritis, arthritis, dactylitis, lymphadenitis,
and orchitis. The prolonged inﬂammation of organs can lead
toblindnessandsterility.Agreaterinﬁltrationoftheskinand
a higher bacterial index are two relevant risks for developing
ENL[9].Improvedstrategiesfortreatmentandmanagement
of these reactions need to be developed [33].
3.4.NerveDamage. Peripheralnervedamageisanimportant
issue in leprosy clinical complication that diminish quality of
lifeofpatients[34].Nerveinvolvementinleprosyaﬀectssen-
sory, motor, and autonomic function of peripheral nerves.
Acute neuritis leads to nerve function impairment, which
if not treated timely and adequately leads to permanent
loss of nerve function causing peripheral sensory and motor
neuropathy [9]. The mechanism underlying nerve injury
in leprosy is poorly understood [35]. TT patients present
granulomatous inﬂammation of peripheral nerves causesJournal of Tropical Medicine 3
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palpable enlargement, which may or may not be painful
and causes sensory and motor loss in the distribution of
the aﬀected nerve. There is enlargement and inﬁltration
of fascicles, which may show caseous necrosis [9]. In LL
patients, nerve function impairment occurs earlier than in
TT patients [35] the destruction of dermal nerves leads to
a glove and stocking neuropathy, peripheral nerve damage
occurs late. There is bacterial proliferation within the
Schwann cells, which leads to foamy degeneration of the
cells losing their regeneration ability [9]. This nerve damage
causes deformities and disabilities are a social stigma and
cause discrimination of patients and their families [34].
4.GenesandItsVariantsAssociatedwith
LeprosyTypesand Immunological Reactions
4.1. Complement Component 3 (C3, 19p13.3-p13.2). Human
complement component forms ester linkages with hydroxyl
groups. Cleavage of C3 exposes a reactive short-lived
thioester moiety in C3b, which covalently attaches to amine
and carbohydrate groups on the target surface. This initial
tagging is quickly ampliﬁed on foreign cells but is immedi-
ately regulated on human cells. Moreover, the reactivity of
the thioester moiety to speciﬁc carbohydrates might lead to
preferential opsonization of foreign particles and represent a
basicpatternrecognitionmechanism[36,37].Inanextrinsic
protease pathway, plasmin, thrombin, elastase, and plasma
kallikrein can also cleave and activate C3. Furthermore,
target-boundMBLcanactivateC3independentlyofmannan
binding lectinserine protease 2(MASP-2),C2, orC4invitro.
The highly abundant C3 can act as a systemic surveillance
protein that has few endogenous ligands but becomes
transformed into one of the most versatile binding partners
upon activation to C3b. The remaining C3a is a powerful
chemoattractant that guides neutrophils, monocytes, and
macrophages toward sites of complement activation and
induces TLR activation in antigen presenting cells [37].
Phenolic glycolipid 1, a major component of M. leprae cell
wall and activated complement component C3, are exposed
on the cell membrane of M. leprae-infected human dendritic
cells. C3 costimulate na¨ ıve T cells via CD46 thus induce the
diﬀerentiation of IL-10-secreting regulatory T cells. In this
way, M. leprae subverts host natural immunity to provoke
an adaptive response that favors bacillary survival [38]. In
populations from Ethiopia and Mali, it was found that
mean C3 serum concentration was lower in leprosy patients
(0.88mg/mL in Ethiopic and 0.73mg/mL in patients from
Mali) when compared with nonleprosy subjects (1.1mg/mL,
both populations) being the lowest C3 levels in each
population found in BL patients (0.62mg/mL) and in TT
patients (0.81mg/mL) from Mali and Ethiopic populations,
respectively. Otherwise C3 phenotypes designated according
to electrophoretic mobility FF (fast-fast), FS (fast-slow), and
SS (slow-slow) were not associated with leprosy. Correlation
of both variables were not reported [22].
4.2.ComplementComponent4B(C4B,6p21.3). Intheclassi-
cal pathway or antibody-dependent pathway of complement,
C1s component cleaves C4 into C4a and opsonin C4b,
thereby exposing a previously hidden thioester and leading
to covalent deposition of C4b on surfaces in the immediate
vicinityoftheactivationsites(opsonization)[37].Deﬁciency
of the C4b isoprotein with higher binding capacity for
thiol groups has been found in association with Immuno
Complexes (IC) diseases involving bacterial or fungal anti-
gens. The non expressed allele C4B∗Q0 increases risk of
ENL probably because C4b is involved in opsonization of
pathogens and immune complex clearance [39] interacting
with C3b and CR1 (CD35) to promote neutrophil-mediated
phagocytosis [37].
4.3. Collagen Type III, Alpha 1 (COL3A1, 2q31). Type III
collagen is a ﬁbrillar-forming collagen comprising 3 α-1
chains and it is expressed throughout embryogenesis. In
adult, type III collagen is an essential component of the
extracellular matrix in a variety of internal organs and skin.
MutationsinCOL3A1genecausetypeIIIandtypeIVEhlers-
Danlos syndrome, a condition of remarkable skin and joint
plasticity that often leads to major blood vessels rupture
in early adult life [40]. Patients homozygous for 250-bp
COL3A1 procollagen III alpha I in Indian population were
associated with the MB form of the disease [23]. A probable
linkage with SCL11A1 located at the neighbor locus 2q35 has
been suggested [24].
4.4. Human β-Defensin 1 (DEFB1, 8p23.1). The human β-
defensin1(hBD-1)hasbeenassociatedwithdiﬀerentallergic
and infectious diseases as well as cancer with a relevant
biological function in protecting mothers against lactational
mastitis and breast-fed infants from diarrhea. In addition,
hBD-1 is capable of chemoattract human immature den-
dritic cells (iDCs) and memory T cells in vitro,p r o m o t e s
caspase-mediatedapoptosisofcancercells,anditsexpression
correlates with insulin and glucose levels [41]. In a Mexican
population DEFB1 gene was associated with LL, the SNP
668C alters one out of ﬁve putative binding sites for
n u c l e a rf a c t o rk a p p aB 1( N F - κB1 or p50/p105) [2, 41]a n d
functionallycorrelateswithlowerconstitutiveexpressionbut
surprisingly also with higher IFN-γ-dependent inducibility
of both hBD-1 and hBD-3 [42]. Thus, diminished NF-κB-
dependent constitutive expression caused by 668C,c o u l db e
a risk factor for developing leprosy into LL been suggested
that this allele is more permissive to M. leprae dissemination
in patients already infected [2]. This probably explains the
extremely rare heterozygote advantage DEFB1 promoter [41,
43, 44] and recurrent overrepresentation of heterozygotes in
this locus [45, 46].
4.5. Ficolin 2 (FCN2, 9q34.3). Ficolin 2 (also called L-ﬁc-
olin or hucolin) is a soluble pattern-recognition molecule
that binds to diﬀerent pathogen-associated molecular pat-
terns (PAMPs), such as lipoteichoic acid, carbohydrates
and acetylated groups, initiating activation complement
through lectin pathway leading to pathogen phagocytosis
[37]. Functional haplotypes of polymorphisms that produce
normalﬁcolin-2levelprotectagainstclinicalleprosy,andlow6 Journal of Tropical Medicine
serum levels of circulating protein are clearly associated with
promoter polymorphisms −986,−602,−4 [47].
4.6. Major Histocompatibility Complex Class I and II (HLA,
6p21.3). The main function of major histocompatibility
complex (MHC) is antigen presentation of processed anti-
gens to T cells. Each classical HLA class I gene encodes a
transmembrane α-chain that noncovalently associates with
β-2 microglobulin (B2M, 15q21–q22.2). The heterodimeric
class I molecule, expressed on all nucleated cells, presents
cytosolic pathogen-associated peptide to CD8+ T cells. In
addition, the classical HLA class I molecules (HLA-A, -B,
and -C) bind peptides of intracellular origin and present
them to CD8+ T cells, engaging killer cell immunoglobulin-
like receptors (KIRs) expressed on natural killer cells been
this as NK “licensing” that render the death of M. leprae-
infected cells [48]. The heterodimeric class II molecule,
expressed on B cells and antigen-presenting cells, presents
extracellular or intravesicular pathogen-associated peptide
to CD4+ Tc e l l s( T H1a n dT H2) resulting in cytokine
production [7]. Polymorphisms in human leukocyte anti-
gens (HLA)-c l a s sI( A ,B ,C )a n dc l a s sI I( D R ,D Q )h a v e
been associated with leprosy types. HLA-DR polymorphisms
modulate the cytokine proﬁle of CD4+ Tf r o mT Ta n d
LL forms against M. leprae-derived heat shock proteins
[49]. HLAs polymorphisms in as HLA A∗0206, A∗1102,
B∗4016, B∗1801, B∗5110, Cw∗0407, and Cw∗0703 have been
associated with leprosy and HLA A∗0101, Cw∗04011,a n d
Cw∗0602 were associated with protection in Indian popu-
lation. Haplotype A∗1102-B∗4006-Cw∗1502 was found in
association with LL patients. Haplotypes A∗1102-B∗4006-
Cw∗0407 and A∗0203-B∗4016-Cw∗0703 were increased in
both LL and TT patients [50]. HLA-class I antigens A9,
A10, A32, B5, B21, Bw4, Bw6, Cw1, Cw2, and HLA-class
II antigens DR9, DR10, DRw52, DQ1, DQ3 were associated
with leprosy. HLA-class I antigens A3, B44, B49, and HLA-
class II antigen DQ5 were found protective in a Turkish
population [51]. HLA-B46 allele and HLAB46/MICA-A5
haplotypeprotectsagainstMBleprosyinChinesepopulation
[52]. In Chinese and Indian populations, HLA-DRB1/HLA-
DQA1 locus, particularly HLA-DRB1∗1501 was associated
with leprosy [6]. Nevertheless, the interpretation of linkage
and association studies of the HLA complex requires caution
because of long-range LD [7].
4.7. Interferon Gamma (IFNG, 12q15). Interferon-gamma
(IFN-γ), or type II interferon, is a cytokine critical for
innate and adaptive immunity against viral and intracellular
bacterial infections and for tumor control. Aberrant IFNG
expression is associated with a number of autoinﬂammatory
and autoimmune diseases. The importance of IFNG in the
immune system stems in part from its ability to inhibit viral
replication directly, but most importantly it derives from its
immunostimulatory and immunomodulatory eﬀects. IFN-
γ is produced predominantly by natural killer (NK) and
natural killer T (NKT) cells as part of the innate immune
response, and by CD4 and CD8 cytotoxic T lymphocyte
(CTL) eﬀector T cells once antigen-speciﬁc immunity
develops [53]. Low levels of IFN-γ in response to M.
leprae antigen in household contacts of MB patients predict
leprosy infection [54]. In a Brazilian population, there was a
protective eﬀect for +874T SNP carriers in IFNG, a gene also
previously reported to be associated with tuberculosis [55].
4.8. Interleukin 4 (IL-4, 5q31.1). Interleukin-4 (IL-4), a TH2
cytokine, regulates expression of a C-type lectin, CD209
antigen (also called Dendritic Cell-Speciﬁc Intercellular
Adhesion Molecule 3-Grabbing Nonintegrin, DC SIGN),
and subsequent M. leprae internalization by Schwann cells
[56]. IL-4 is expressed in skin lesions of MB patients [56]
and its −590C allele decreases leprosy susceptibility [57]. IL-
4 has been shown to act downregulating TLR2 and IL-10
on monocytes. IL-10 suppresses production of IL-12 [9]a n d
also downregulates antimycobacterial peptide cathelicidin
(LL-37) [58] apparently in a negative feedback mechanism
[59].
4.9. Mannose-Binding Lectin 2 (MBL2, 10q21.1). Mannose
binding lectin 2 (MBL2) is an important component of
the ﬁrst-line defense against infections. MBL2 acts as a
pattern recognition molecule of a wide range of infectious
agents recognizing sugar moieties such as mannose, N-acetyl
glucosamine, fucose, and glucose present on the surface of
several microorganisms, leading to their phagocytosis and
MBL-associated protease-2-dependent activation of com-
plement [60] through mannan binding lectin serine pro-
teases (MASPs) such as MASP2 [61]. MBL also can induce
phagocytosis in the absence of complement activation
through an interaction with one or more collectin receptors
[62]andisabletoinduceinﬂammatoryresponsesbybinding
to receptors on phagocytes [60]. MBL deﬁciency, which
mainly results from three relatively common single-point
mutations in exon 1, reduces phagocytosis and internaliza-
tion of intracellular pathogens protecting the host against
intracellular infections such as leprosy and interestingly
predisposes both to infection by extracellular pathogens
and to autoimmune disease [60]. A signiﬁcant negative
association of MBL deﬁciency (<100ng/mL) was observed
with LL patients when compared with controls and TT
patients, suggesting a protective role for MBL deﬁciency
against the development of the most severe MB form of
leprosy [63] explained because MBL deﬁciency could be
advantageous against intracellular pathogens that exploit
complement deposition on their surface to enhance uptake
into phagocytes such as the case of M. leprae [14, 60]. SNP
G161A was associated with protection from LL and C154T
as well as G170A show no association in a population from
Nepal [64]. The LYPA haplotype of MBL2 was associated
with susceptibility to leprosy per se and to progression to the
lepromatous and borderline forms of the disease in subjects
from southern Brazil [25]. Recently, it has been shown that
MBL serum levels in leprosy patients are inﬂuenced by age,
those patients aged >40 years had decreased MBL levels
compared with patients aged ≤40 years. No association
was found among analyzed SNPs in MBL2 with leprosy
susceptibility or with any of its clinical forms [65].Journal of Tropical Medicine 7
4.10. Mannose Receptor, C-Type 1 (MRC1, 10p12.33). The
ﬁrst genome-wide linkage leprosy study revealed a high
LOD score in locus 10p13 among Indian populations [66].
Mannose receptor 1 gene (MRC1 or CD206) in this locus,
speciﬁcally 10p12.33, codiﬁes for mannose receptor C-type
lectin (MR) on macrophages membranes, which recognize
M. leprae cell wall mannose residues, as well as ovalbumin
and zymosan. Notably, cellular entry through MR has been
correlated with M. tuberculosis virulence [67]. From 75
analyzed SNPs in MRC1 (101.8 Kb), G396S (rs1926736)
was the only relevant. 396S allele of MRC1 is the only
nonsynonymouspolymorphismofexon7andwasassociated
with protection against MB leprosy in 490 simplex and 90
multiplex Vietnamese families (704 patients). Similarly, but
in haplotype analysis, when 399A and 407F polymorphisms
are present, 396G allele was also the risk factor in a case-
control study of Brazilian patients with MB leprosy. It has
been suggested that MR-M.leprae interaction is modulated
by an additional accessory host molecule of unknown
identity [68].
4.11. Nucleotide Oligomerization Domain 2 (NOD2, 16q12).
Nucleotide oligomerization domain 2 (NOD2, also called
caspase recruitment domain-contanining protein 15,
CARD15) is part of intracellular PAMPs known as NOD-
like receptors (NLRs). Triggered by muramyl dipeptide
recognition, NOD2 interacts with the adapter protein RIPK2
(but not with pyrin domain containing-3, NALP3, another
member of NOD-like receptor family) to initiate NF-κB
pathway signaling through the recruitment of the inhibitor
of NF-κB kinase (IKK) complex to the central domain of
RIPK2 [6, 69]. NOD2 interacts with the autophagy-related
gene 16L1 (ATG16L1) and seems to be relevant inducing the
autophagosome complex assembly (ATG5-ATG12) which
induces autophagy in DCs leading to bacterial handling
and generation of MHC class II antigen-speciﬁc CD4+
T cell responses in DCs. The polymorphisms rs9302752
and rs7194886 were associated with leprosy in Chinese
population [26] but not in Indian or Mali population [70].
4.12. Parkin 2 and Parkin 2 Coregulated Gene (PARK2 and
PACRG, 6q25.2-q27). PARK2 (parkin) encodes an E3 ubiq-
uitin ligase, with a role in the ubiquitin-proteasome pathway
ofintracellularproteindegradation.PARK2alsoregulatesthe
processing of protein antigens within macrophages, thereby
aﬀecting antigen presentation [35] and it is involved in
cellular antioxidant response and T cell anergy [71]. PARK2
was named for its association with an early-onset form
of Parkinson disease [35]. PARK2 is not only expressed
in dopaminergic neurons but also in monocyte-derived
macrophages and Schwann cells, primary host cells of M.
leprae [71]. PACRG is a Parkin-coregulated neighbor gene of
unknown function [12, 72] but together with PARK2 have
been proposed to be involved in degradation of TLRs and
NF-κB signaling pathway proteins [71].
In families from Southern Vietnam was reported a
leprosy susceptibility region in 6p25. Of seven microsatel-
lite markers underlying the linkage peak, alleles of two
markers (D6S1035 and D6S305) showed strong evidence for
association with leprosy [72]. In a study of 197 simplex
Vietnamese families, from 81 SNPs analyzed, 19 SNPs
clustered in the 5 PARK2 and PACRG regulatory region and
were signiﬁcantly associated with leprosy. Common allele
T of the ﬁrst intron of PACRG, PARK2 e01 (−2599), and
rare allele C of rs1040079 were independently associated
with an increased risk of leprosy and solely this two Tag
SNPs explain the strong association in this region [12]. The
association was reproduced in a Brazilian population (587
cases, 388 controls) where possession of as few of two of
the 17 risk alleles was highly predictive of leprosy. Again,
PARK2 e01 (−2599)a n drs1040079 were among the three
most signiﬁcantly associated SNPs in this population [12].
4.13. Solute Carrier Family 11, Member 1 (SLC11A1, 2q35).
SLC11A1 is expressed in spleen, lung, liver, and most inten-
sively, in peripheral blood leukocytes [14]. SLC11A1(for-
merly NRAMP1) is a divalent cation transporter, when a live
bacteria is phagocytosed. SLC11A1 protein is recruited to the
macrophage phagosome membrane and limits pathogens’
iron availability by exporting it from the phagolysosome
[73, 74]. It has been suggested that SLC11A1 may inﬂuence
the expression of MHC class II molecules, regulation of
expression of TNFA, and induction of nitric oxide synthase
[35]. By a genome-wide scan in Vietnamese families, it
was found linkage with Mitsuda response in SLC11A1
(2q35) and 17q21-25 loci, two regions previously linked to
mycobacterial infection, granulomatous, [75]a sw e l la se a r l y
onset [76, 77] and severe asthma [78]. These similarities
suggest that some common exacerbated epithelial responses
may be regulated by SLC11A1 and also by a major uniden-
tiﬁed gene(s) in 17q21-25 [75]. The 3 UTR TGTG deletion
in SLC11A1 was associated with MB subtype in a Mali
population and heterozygotes were more frequent among
MB than PB patients [79, 80]. It has been proposed that
allele 2 of the SLC11A1 promoter is an independent genetic
factor that predisposes cells to enable pathogen survival,
probably due to its low eﬃciency in iron transport, but
establishment of the infection and disease development are
probably conditioned by additional genetic factors [81].
4.14. Toll-Like Receptor 1 (TLR1, 4p14). Toll-like receptors
are cell-surface molecules that play an important role in the
recognitionofpathogens[35,82].TRL1:TLR2heterodimers
recognize triacyl lipopeptides from Gram-negative bacteria
and mycoplasma, two of the three lipid chains of the
triacylated lipopeptide interact with TLR2 and the third
chain binds the hydrophobic channel of TLR1 and lead
to NF-κBa c t i v a t i o n[ 82]. The association between the
hypofunctional TLR1 phenotype and protection against
leprosy suggests that M. leprae may utilize TLR1 as part of
its pathogenic mechanism [6]. The T1805G (rs5743618 or
I602S) variant presumably downregulates TLR1 expression
on the cell surface and also causes abnormal signaling [83,
84] and has been associated with a decreased incidence of
leprosy and with protection against reversal reaction [83]
probablydiminishing antimycobacterialcathelicidin(LL-37)8 Journal of Tropical Medicine
expression [4, 5]. Allele 1805G has been associated with
diminishedproductionofIL-1β,IL-6,andTNFinperipheral
blood mononuclear cells stimulated with M. leprae [84, 85].
TLR1 248SS is associated with protection against leprosy
[86].
4.15. Toll-Like Receptor 2 (TLR2, 4q32). TLR2 is involved
in the recognition of a wide range of pathogen-associated
molecular patterns (PAMPs) as lipoarabinomannan from
mycobacteria, lipopeptides from bacteria, peptidoglycan and
lipoteichoic acid from Gram-positive bacteria, zymosan
from fungi, tGPI-mucin from Trypanosoma cruzi and the
hemagglutinin protein from measles virus [82], and in
combination with MARCO and CD14 recognizes mycobac-
terial trehalose 6, 6 -dimycolate (TDM/cord factor) [87].
Lipoproteins trigger host responses via TLR2. TLR2:TLR6
heterodimers are activated by diacylated lipoproteins from
Gram-positive bacteria and mycoplasma and TRL2:TLR1
by triacylated lipoproteins. Both heterodimers form a m-
shaped structure and induce mainly inﬂammatory cytokines
[82]. Furthermore, this increased ability to generate diversity
in PAMP recognition-forming dimers with TLR1 or TLR6,
TLR2 also has the ability to act together with other corecep-
tors on the cell surface that assist PAMP recognition. These
include dectin-1, a C type lectin that binds fungus β-glucan
and induces internalization and CD36, which act together
with TLR2-TLR6 heterodimer to mediate the sensing of
some but not all TLR2 agonists [82]. TLR-dependent IL-
12p40 production was detected from primary human mono-
cytes and monocyte-derived DCs after stimulation with a
19- or 33-kDa M. leprae lipopeptide [88]. However, some
TLR2 nonsynonymous polymorphisms in Japanese patients
were not associated with leprosy [89]p r o b a b l yb e c a u s e
their variants are in a dispensable region of the receptor.
Nonsynonymous substitution R677W of TLR2 gene was
found in 10 out of 45 LL patients but absent in TT or
nonlepromatous controls [90]. A study in Indian population
revealsthatthesupposedmutationisinapseudogenelocated
23 Kb upstream of TLR2, who shares 93% homology with its
exon 3 [91]. A synthetic lipopeptide consisting of N-terminal
portion of M. leprae 19-kDa lipoprotein triggered and
increasedthenumberofapoptoticSchwanncelllineST88-14
by a TLR2-mediated mechanism causing nerve damage [92].
Also, homozygosity for the 280-bp microsatellite in TLR2
gene strongly increased the risk of RR in Ethiopian patients
[93].TLR2 and TLR1 expression was relatively much weaker
in LL skin biopsies [88].
4.16. Toll-Like Receptor 4 (TLR4, 9q32-q33). TLR4 is a cell-
surface receptor which recognizes respiratory syncytial virus
fusion proteins, Streptococcus pneumoniae pneumolysin,
mouse mammary tumor virus envelope proteins, and plant-
derived cytostatic drug paclitaxel, also in complex with
MD2+ engages bacterial lipopolysaccharide (LPS). There
are two main possible routes of TLR4 activation, the di-
rect route that leads to an early NF-κB response and
inﬂammatory cytokines expression and the indirect route
through endosome leading to a subpathway of late NF-κB
activation and inﬂammatory cytokines proﬁles and to an
alternative subpathway where Interferon Response Factor 3
(IRF3) induces type I IFN expression [82]. TLR4 is required
for the host defense against M. tuberculosis and probably
mediate response to mycobacterial heat shock proteins [4].
Furthermore, stimulation of monocytes with M. leprae
partially inhibited their subsequent response to LPS. SNPs
896G/A(D299G)and1196C/T(T399I)wereassociatedwith
protection against leprosy in Ethiopic patients [94].
4.17. Tumor Necrosis Factor (TNF, 6p21.3). Tumor necro-
sis factor is a proinﬂammatory and immunostimulatory cy-
tokine secreted predominantly by monocytes/macrophages
that has eﬀects on lipid metabolism, coagulation, insulin
resistance, and endothelial function [14]. High levels of
circulating TNF (>1000pg/mL) have been demonstrated in
the plasma of some individuals with ENL who also develop
erythema multiforme, a skin disease characterized by papu-
lar or vesicular lesions and reddening or discoloration of
the skin often in concentric zones about the lesions [27].
In vitro peripheral blood mononuclear cells (PBMCs) from
individuals with ENL secrete the highest amounts of TNF
following stimulation with lipoarabinomannan, the main
component of cell wall, when compared with other forms of
the disease. It has been reported that half of BT patients have
elevated serum levels of TNF [27].
4.18. Vitamin D Receptor (VDR, 12q12-q14). Upregulation
of the Vitamin D receptor gene (VDR)o nm a c r o p h a g e s
is associated with increased intracellular killing of M.
tuberculosis. I nh u m a nm o n o c y t e sa n dm a c r o p h a g e s ,t h e2 5 -
hydroxyvitamin D3-1a-hydroxylase (CYP27B1) which con-
verts the 25, D into the active 1, 25 form, upregulating and
activatingthevitaminDreceptoranddownstreaminduction
of the antimicrobial peptide, cathelicidin [5]w h i c hi sa c t i v e
against M. tuberculosis [95–98] and could be also active in
vivo against M. leprae, but this deserves further investigation
[2, 41]. In Indian population, homozygotes for the alternate
alleleshavebeenassociatedwithLLandTT,respectively[99],
and in Mexican population TT genotype of VDR obtained
with TaqI (exon 9, codon 352) has been associated with LL
[100].
5. PotentialbutScarcely Explored
CandidateGenes
5.1. Hydroxyacid Oxidase 1 Gene (HAO1, 20p12). The mark-
er D20S115 in locus 20p12 that was associated with leprosy
in Indian population [10] lies near atopic dermatitis with
asthma loci (ATOD3) and also associated with psoriasis
[101]. The closest gene to the marker D20S115 in locus
20p12 (∼0.2 Mb) is HAO1, hydroxyacid oxidase 1 [102].
This enzyme is expressed predominantly in the liver and
pancreas and utilizes a ﬂavin cofactor to convert glycolate
and 2-hydroxy fatty acids with the concomitant reduction
of molecular oxygen to hydrogen peroxide [103]. It could
be worthwhile to analyze its role in leprosy, especially in
LL patients, whose lesions accumulate host-derived oxidized
lipids [4], knowing that M. leprae has lost most of the genesJournal of Tropical Medicine 9
involvedinthedetoxiﬁcationofreactiveoxygenandnitrogen
species [104] and have a unique truncated hemoglobin [105,
106].
5.2. Toll-Like Receptor 6 (TLR6, 4p14). TLR6 is a cell-surface
receptor and TLR6:TLR4 heterodimer with coreceptor
CD36recognizesoxidizedlow-densitylipoprotein(ox-LDL),
a known danger-associated molecular pattern (DAMP) [82].
TLR6 regulates M. leprae-Schwann cells interactions, and
mainly in LL lesions, leads to phagocytosis and subsequent
signaling for induction of lipid droplets (LDs or lipid
bodies) biogenesis in infected cells, LDs favor mycobacte-
rial survival and persistence, and thus are a hallmark of
the foamy phenotype of M. leprae-infected Schwann cells
[107]. LL lesions have a marked upregulation of host lipid
metabolism genes when compared with TT lesions. Virchow
cells (lepra cells or foam cells) are macrophages containing
intracellularaccumulationofaspeciﬁchost-derivedoxidized
phospholipid, 1-palmitoyl-2-(5, 6-epoxyisoprostane E2)-sn-
glycero-3-phosphorylcholine (PEIPC) [4]. Theoretically, if
TLR6 is mutated at its heterodimerization site it could not
form the TLR2:TLR6, and the subsequent recognition of
PAMPs or DAMPs should be abrogated. This epistasis
should be considered in studies of TLR2 [82]. Biomedical
relevant TLR6 polymorphisms remain to be discovered and
a bioinformatic transcriptional impact could be used as a
polymorphism sieving method [108].
5.3. Toll-Like Receptor 8 (TLR8, Xp22.3-p22.2). TLR8 is ex-
pressed exclusively in intracellular vesicles such as the endo-
plasmic reticulum, endosomes, lysosomes, and endolyso-
somes, where it recognized microbial nucleic acids. TLR8
is expressed in various tissues with the highest expression
in monocytes and is upregulated after bacterial infection.
TLR8 mediates the recognition of R-848 and viral ssRNA
but this function seems to overlap with TLR7 [82]. Four
polymorphisms in TLR8 showed protection against TB [4]
and it will be worthwhile to assess them in leprosy suscep-
tibility. Furthermore, their localization in a sexual chromo-
some could be relevant in gender-associated susceptibilities
(leprosy prevalence presents male: female ratio of 1.5–2.0:1)
[19] and X-linked heritabilities, although no linkage of
leprosy susceptibility with the X chromosome has been
found to date [109].
6. Further Considerations in
LeprosyImmunogenetics
6.1. Homo Sapiens-M. Leprae Genetic Interaction and Treat-
ment Eﬀect. With the above mentioned, it is now clear that
most of the variants in clinical states in leprosy could be
due to host genetics [2, 7, 8, 24, 110–112], and it is also
relevant to study whether M. leprae variants [104, 110–116]
and its genetic interaction with human genome accounts
for some clinical variability, specially for drug-resistant
leprosy in M. leprae genes folP1, rpoB, and gyrA which
are associated with resistance to dapsone, rifampicin, and
oﬂoxacinrespectively[117,118].Alsoofrelevantimportance
istheeﬀectofimmunosuppressivedrugsonleprosyreactions
[35].
6.2. Ethnic Susceptibility Diﬀerences due to Genetic Back-
ground and Technical Bias. It is relevant to mention that the
ethnic genetic pool can aﬀect susceptibility to disease [119]
for example, the signiﬁcant diﬀerences of polymorphism
frequencies in DEFB1 gene among Mexican population
whencomparedwithGermanandChinesepopulations[46],
which gene, as above mentioned was associated with LL
[2]. It will be worthwhile to carry out susceptibility studies
in other populations and be cautious with meta-analysis
results in leprosy, because the relevancy of a gene in the
disease could be inﬂuenced to allele/genotypes/haplotypes
frequencies according to ethnic background [119, 120].
Arelevantissueofconcernisduetotechnicallimitations,
for example, the fact that commercial microarrays do not
contain all relevant probes for SNPs associated with leprosy
and many biomedical important polymorphisms are poorly
represented. These technical limitations lead to a bias in the
scientiﬁc interpretation of results and this issue is usually
notmentionedingenome-wideassociationstudies(GWASs)
and authors still claim for a “complete genome” analysis
[121].
7. Efﬁcient Prevention,FastDiagnostics,
andSuccessful Therapeutics, the Goalof
TranslationalMedicine:Leprosyas
anExample
One potential application of genetic association studies’
conclusions could be a starting point to a better understand-
ing of disease by proposing candidate genes to be assessed
with in vitro and in vivo studies, and also to evaluate the
relative impact of genetic variants related to ethnicity versus
environmental factors, in order to design better alternative
diagnostics and therapeutics that could solve the public
health problem that leprosy still represents.
Nevertheless, an imminent eﬀect in patients with genetic
testing information could be distress and anxiety so this
information must be handled wisely by researchers and cli-
nicians [122] because education plays a crucial role in the
management of leprosy, is relevant to carefully explain to
the aﬀected individual and their family the infectious nature
of the disease, and is curable [9]. Now with information
availability from the ongoing 1000 Genomes [123, 124]a n d
Human Variome projects the situation claims priority, and
ethical standards must be established, reviewed, and updated
constantly [125].
One recent and promising proposal in infectious dis-
eases treatment comprising leprosy is the administration
of antimicrobial peptide elicitors (APEs) speciﬁcally with
the posibility of upregulating antimicobacterial host defense
peptides as hBD-1 [41, 126] and cathelicidin LL-37 [127,
128] or the classical approach of APs direct administration
[129], in the latter case with its inherent drawbacks [41].
Eﬀectiveness and safety of APEs or APs in clinical practice
is an exciting upcoming event. Even though the leprosy10 Journal of Tropical Medicine
morbid map is far from complete, this is just one potential
application that must be moved from bench to bedside.
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